GlobeNewswire by notified

Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

Share

The companies will leverage their combined experience in the development of conjugate vaccines for their clients

  • Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development
  • Intravacc has IP and know-how in vaccine conjugation and manufacturing of carrier protein based products
  • Clients active in conjugate vaccines will benefit from a seamless solution across development and manufacturing

BILTHOVEN, The Netherlands, March 28, 2024 (GLOBE NEWSWIRE) -- Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines, and Primrose Bio, a biotechnology company with leading technologies that improve the manufacturing of next-generation therapeutics, announced a strategic partnership to enhance the development and supply of conjugate vaccines. Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.

Dr. Jan Groen, Intravacc’s CEO, says:
We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose's cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide."

Dr. Helge Zieler, Primrose Bio’s CEO, further comments:
“Expanding the capability of our PeliCRM197® franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development. With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole."

This partnership harnesses the synergistic strengths of both companies, fostering innovation and efficiency in vaccine development. Intravacc contributes its comprehensive technical expertise, state-of-the-art facilities, and robust capabilities in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines. Primrose Bio complements this with its ultra-pure production, supply chain, and regulatory support for the PeliCRM197® carrier protein, a vital ingredient in conjugate vaccine formulations and the only commercial CRM197 used in commercial vaccines available for purchase. This carrier protein is offered in a range of quantities and grades, from milligrams to kilograms, both for research and GMP applications. The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients.

About Intravacc

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global CDMO for infectious diseases and therapeutic vaccines. As an established independent CDMO with many years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology world-wide for many vaccines including polio, measles, DPT, Hib and influenza. Approximately 30% of childhood disease vaccines are based on Intravacc’s know-how and proprietary technology. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies for partners around the world, including biotech and pharmaceutical companies, governmental agencies and NGOs. With its innovative vaccine platforms OMV-Vacc, Cell-Vacc, Con-Vacc, E.co-Vacc and good manufacturing procedures (GMP) facilities the company is well positioned to address the unmet needs in the vaccine and immune therapy market.

About Primrose Bio, Inc.

Primrose Bio was established in 2023 from the merger of Primordial Genetics, Inc. and Ligand Pharmaceuticals’ Pfenex Expression Technology® platform and PeliCRM197® carrier protein franchise. This combination brings together Primordial’s Prima RNApols and Function Generator platforms to enhance the development and manufacturability of complex protein- and nucleic acid-based products for human and animal health, vaccines, and non-pharmaceutical uses. Top pharmaceutical companies, including Merck, Jazz Pharmaceuticals, Serum Institute of India, and Alvogen, use these technologies in their approved products. Additional clients include Arcellx, Arcturus, and a host of others well known players. For more details, visit www.primrosebio.com.

Contact info

Intravacc
Dr. Jan Groen, CEO
P: +31 30 7920 454

Media relations Intravacc
P: +31 30 7920 579
E: press.office@intravacc.nl

Primrose Bio 
Melanie Venter-Roit, Communications 
P: +1 858 344 4419 
E: media@primrosebio.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea7 awarded a contract for the Belinda field in the UK North Sea25.5.2024 14:01:09 CEST | Press release

Luxembourg – 25 May 2024 - Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base and for controls at the Evelyn valve skid. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio25.5.2024 12:15:00 CEST | Press release

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor,demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atr

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo25.5.2024 12:00:00 CEST | Press release

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3Fabhalta showed a favorable safety profile with no new safety signals1C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9 Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to support

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye